Navigation Links
A New Era in the Application of Lab-on-a-Chip to Rapid Point-of-Care Diagnosis
Date:5/17/2009

ATLANTA, May 17 /PRNewswire/ -- Hai Kang Life Corporation Limited (HKLife) announces further developments of its patented field-assisted LOAC (Lab-on-a-Chip) system, EFADchip technology at the BIO 2009 International Convention, the Global Event for Biotechnology held in Atlanta, through 18-21 May 2009. The BIO International Convention is the largest annual gathering for the biotechnology industry and attracts the biggest names in biotech, offers key networking and partnering opportunities and provides insights and inspiration on the major trends affecting the industry.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO)

Concurrent with the BIO Convention, HKLife also launches two new additions to its existing product portfolio: a Diagnostic Test Kit for Influenza Type A/H1N1 and a MOBILE FIELD UNIT ensuring effective deployment of diagnostic testing for point-of-care applications. The test kits have been developed in rapid response to the 2009 novel influenza A (H1N1) virus outbreak, as the World Health Organization (WHO) has called for all member states to enhance surveillance and diagnostic capacities for influenza and other acute respiratory infections. The MOBILE FIELD UNIT will deliver sensitive and accurate diagnostic capabilities to resource-limited urban, rural and remote locations where access to conventional clinical laboratories may be precluded.

Company Founder, Chairman and CEO, Professor Albert C. H. Yu will be speaking at the Bio Business Forum on Wednesday 20 May. Dr Yu is a renowned neuroscientist and bio-entrepreneur. His broad, cross-cultural experience and active involvement in both the academic and business environment led to the strategic vision behind the success of the HKLife team. Meanwhile, COO and General Manager, Dr. Terence L.T. Lau has been instrumental in driving HKLife and its subsidiaries. His success and achievements in both academia and bio-commercial endeavors continues to bring HKLife's vision of becoming "the world's leading molecular diagnostics company" closer to fruition. HKLife has pioneered the development of advanced and ground-breaking DNA-based diagnostic technologies and leveraging a unique business model, steered the development of its novel EFADchip technology into a fully-functional platform. Thus, the company has created the impetus to revolutionize the practice of clinical and point-of-care diagnostics and ultimately establish HKLife as a prominent player in driving Asia into the globally competitive biotechnology arena.

The EFADchip technology uses electric field-assisted DNA hybridization to accelerate the detection of biological samples on a single chip. The key differentiator of this technology is the use of a dielectric material for both electric field generation and capture probe DNA immobilization, thus avoiding adverse electrochemical effects that can lead to reduced sensitivity and accuracy of detection. The EFADchip is fabricated using widely available materials and common photolithographic techniques well known in the miniaturized electronics industry, resulting in a structure that is inherently stable under varying ambient conditions.

Type A/H1N1 detection kits are available across three diagnostic technology platforms: VDS makes use of the highly advanced nucleic acid sequence-based amplification - enzyme-linked oligonucleotide capture (NASBA-EOC). The VDS technology has an advantage of not requiring the use of specialized equipment; VetDetect utilizes real-time reverse transcriptase polymerase chain reaction (RT-PCR) and VetScreen employs the conventional gel-based RT-PCR technique. All three platforms are highly sensitive and specific, giving rapid and accurate results within two to four hours.

HKLife's MOBILE FIELD UNIT is also available with a choice of technology platforms, either NASBA-EOC (enzyme-linked oligonucleotide capture) or a recently developed, patented and validated NASBA-POC (point-of-care) molecular diagnostics technology. Convenient, reliable and specific amplification of the target RNA is achieved under isothermal conditions, alleviating the requirement for thermo-cycling. Combined with a simple optical method of detection that does not require complex fluorescence equipment, the system offers sensitivity comparable to Real-Time PCR.

About HKLife:

Hai Kang Life Corporation Limited, formerly known as Hong Kong DNA Chips, was established with independent research funding in 1999. The company is strategically positioned at the hub of Asian biotechnology, equipped with the most advanced research and production facilities in both Beijing and Hong Kong. Strong working relationships with academic institutions, government and industry partners have created a solid foundation for business success. The world-class team of scientists, engineers and technologists, supported by a highly esteemed Scientific Advisory Board, is committed to maintaining HKLife's position at the forefront of bio-business, leveraging best practices from both East and West.

For more information about HKLife's EFADchip, Diagnostic Test Kit for Influenza Type A/H1N1 and MOBILE FIELD UNIT visit http://www.haikanglife.com

Contact: media@haikanglife.com

Visit us at BIO, booth H2249


'/>"/>
SOURCE Frost & Sullivan
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. European EMEA Acceptance of Marketing Authorization Application Filing for SNT-MC17 in Friedreichs Ataxia by Santhera
2. Barr Confirms Filing an Application With a Paragraph IV Certification for Femcon(R) FE Chewable Oral Contraceptive Product
3. KineMed to Collaborate With Merck KgaA to Validate New Applications for Drug Development Candidates
4. MichBio Announces Expo Tours; Extends Deadline for Innovator Showcase Applications
5. FDA Accepts ISO-Vorin(TM) New Drug Application Amendment Submitted by Spectrum Pharmaceuticals
6. Isis Announces $4.2 Million in Government Contracts Awarded to Its Ibis Subsidiary for Biodefense Applications Development
7. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
8. Nitecs IND Application for Clinical Development With Lodotra Accepted by the FDA
9. CV Therapeutics Submits Supplemental New Drug Application for Ranexa(R) (ranolazine extended-release tablets)
10. National Stem Cell Holding Announces Patent Application for Newly Discovered Cellular Derived Biomaterials for Anti-Aging Applications
11. Laser Energetics to Integrate BrightStar(TM) Alexandrite Lasers in Medical and Dental Applications
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 23, 2017  BioPharmX Corporation (NYSE MKT: BPMX), ... dermatology market, today reported financial results for the ... will provide an update on the company,s clinical ... "We are pleased to report that last ... said President Anja Krammer. "We achieved key clinical ...
(Date:3/23/2017)... March 23, 2017 According to a report ... derivatives market is fragmented due to the presence of a large pool ... Thermo Fisher , and Sigma-Aldrich, compete with each other in ... collectively, held more than 76% of this market in 2016.  ... As of now, a ...
(Date:3/22/2017)... Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), today announced a ... Biobank and GSK to generate genetic sequence data from the ... will enable researchers to gain valuable insights to support advances ... of serious and life threatening diseases. ... Genetic evidence has revolutionized ...
(Date:3/22/2017)... Mass. , March 22, 2017 Good ... that it has eclipsed the 130 million covered lives ... Blue Shield of Texas . With ... the Company continues to enjoy strong payor acceptance based ... its clinical programs and genetic counseling, its industry-leading customer ...
Breaking Biology Technology:
(Date:2/26/2017)... 2017  Securus Technologies, a leading provider of ... safety, investigation, corrections and monitoring, announces the appointment ... "Too often, too many offenders return to ... are trying to tackle this ongoing problem and ... family members. While significant steps are underway, Securus continues ...
(Date:2/21/2017)... Der weltweite Biobanking-Sektor wird bis ... Gespräch mit mehr als 50 Vertretern aus verschiedenen Branchen wurde ... um diese Prognose zu realisieren. ... Zu den Schwierigkeiten ... Mittel für die Biobank, die Implementierung Zeit sparender Technologien, ...
(Date:2/13/2017)... 13, 2017 Former 9/11 Commission border counsel ... Janice Kephart of Identity Strategy Partners, LLP, ... Trump,s "Executive Order: Protecting the Nation From Foreign ... "As President Trump,s ,Travel Ban, Executive Order ... essentially banned the travel ban, it is important that ...
Breaking Biology News(10 mins):